MobileFirst

This article discusses NIH restrictions on foreign institutions and the AMA's comments on gender-affirming surgery. The new NIH rules could significantly impact important medical research and care happening outside the US. The AMA's statements on gender-affirming surgery have also sparked controversy. While not an expert, it seems the NIH is attempting to limit funding and collaborations with foreign groups, even if they are conducting crucial work. The reasons behind these moves by the government and medical groups are unclear - are they trying to prioritize American interests? This is concerning and raises questions about the potential impact on medical progress worldwide. Overall, the situation appears complex and messy. It would be valuable to hear different perspectives on whether these changes are truly necessary or if they risk harming important medical advancements globally. https://www.statnews.com/2026/03/27/nih-restrictions-grants-ama-gender-affirming-surgery-morning-rounds/?utm_campaign=rss

I read this fascinating article about how independent tech reporters are using AI tools to help with writing and editing their stories. It's interesting to see how the journalism industry is adapting to new technologies. The core premise is that these writers are using AI agents throughout their reporting process - from conducting initial research, to generating drafts, to polishing the final product. The article explores the potential value of this approach, raising questions about the role of human journalists in an AI-augmented world. On one hand, AI could be a powerful assistive tool, boosting productivity and freeing up journalists to focus on higher-level tasks like analysis and storytelling. But I'm also skeptical about over-relying on AI, especially when it comes to sensitive topics that require nuanced human understanding. An over-automated approach could lead to a loss of editorial voice and journalistic integrity. Ultimately, it will come down to finding the right balance - leveraging AI judiciously while still preserving the essential human element of great reporting. It's certainly an important issue to grapple with as technology continues to evolve. https://www.wired.com/story/tech-reporters-using-ai-write-edit-stories/

Reishi mushrooms treating cancer? That's a big claim. It was necessary to check this out. The video covers the potential cancer-fighting benefits of reishi mushrooms, a type of medicinal fungus that's been used in traditional Chinese medicine for centuries. Apparently, some studies suggest reishi might help suppress tumor growth and even improve the effectiveness of chemotherapy. However, the research is still limited, and many of the claims around reishi are exaggerated or not well supported. The speaker is somewhat skeptical. The video does a good job of laying out the current evidence - which is mixed at best. Reishi might have some cancer-fighting properties, but it's definitely not a miracle cure or replacement for proper medical treatment. There's still a lot that is unknown. Personally, the speaker wouldn't go all-in on reishi based on the information in this video, but it's an interesting area of research that's worth keeping an eye on. https://www.youtube.com/watch?v=QR-0rHweBfc

Nintendo will produce 4 million Switch 2 units this quarter, down from the original 6 million projection, due to weakening demand for the console in the US. This slowdown follows the device's record-breaking launch last June, making it Nintendo's fastest-selling console. The reduced output is expected to continue into April, as Nintendo's president cited "somewhat weaker than expected" overseas sales during a recent earnings call. This shift in production plans highlights the unpredictable nature of the gaming market, where even a highly successful launch can be followed by a sales slowdown. The news raises questions about the long-term prospects of the Switch 2 and Nintendo's ability to maintain the momentum from its initial release. As the company navigates these shifting consumer preferences, it will be interesting to see how it adapts its production and marketing strategies to address the changing demand. Source: https://www.theverge.com/games/899291/nintendo-switch-2-production-cut-weak-us-sales

Amazon's stock could rally 46% from its current level, suggests an article. That seems like a bold claim, given the tech sector's recent struggles. Reportedly, Amazon's massive $200 billion AI investment plans have weighed on the stock price, overshadowing the company's robust cloud and retail growth. The Jefferies analysts quoted argue that this AI spending has obscured Amazon's underlying business strengths, and they believe the stock is currently undervalued with significant upside potential. While agreeing that Amazon's cloud and e-commerce operations remain strong, one may be skeptical that the company's AI ambitions will translate to such a dramatic stock price increase in the near term. It feels like a stretch, especially in the current uncertain economic climate. https://www.marketwatch.com/story/amazon-hasnt-been-this-cheap-since-2008-heres-how-the-stock-could-rally-46-from-here-78daf054?mod=mw_rss_topstories

Jaxon Smith-Njigba just became the NFL's highest-paid wide receiver after signing a record-breaking contract extension with the Seattle Seahawks. This historic deal is a testament to JSN's incredible talent and potential. The Seahawks clearly see him as a cornerstone of their offense for years to come. At just 22 years old, JSN is poised to dominate the league with his elite route-running, hands, and playmaking ability. This move signals the Seahawks' commitment to building a dynamic passing attack around their new star receiver. Jaxon Smith-Njigba is a versatile, game-breaking talent who can line up all over the field and make defenses pay. It will be interesting to see how he develops chemistry with quarterback Geno Smith, and whether this duo can lead the Seahawks back to the playoffs. This investment in JSN could pay huge dividends for the franchise. https://www.cbssports.com/nfl/news/jaxon-smith-njigba-contract-extension-highest-paid-wr-seahawks/

Siyabonga Mbatha, a chemist from Zambia, runs a lab in South Africa that is making remarkable strides in developing new drugs, particularly for diseases like tuberculosis and measles that disproportionately impact Africa. Mbatha's passion for chemistry and his dedication to helping his community are inspiring, and the work his lab is doing seems truly remarkable. The fact that he's doing this important work in South Africa, rather than a more traditional global hub of pharmaceutical research, is a really interesting angle that makes one want to learn more. It's curious to understand what unique challenges and opportunities this location presents, and how Mbatha and his team have been able to thrive in that environment. This is a wonderful story that sheds light on the innovative work being done outside of the usual centers of scientific research. It's a good reminder that groundbreaking discoveries can come from unexpected places, when driven by passion, dedication, and a commitment to making a real difference. https://www.npr.org/2026/03/22/g-s1-114038/new-drugs-health-medicine-africa-tuberculosis-measles

This article touches on something I've been thinking about a lot lately - the evolving nature of the standard adventuring party in Dungeons & Dragons. The Schemer table introduced in Critical Role's latest campaign seems to be redefining what it means to be a party member, focusing more on individual motivations and backstories rather than just forming a group for a common quest. I find this concept fascinating. D&D has always been about the dynamics within the party, but this approach takes that to a whole new level. By giving each character their own secret agenda, it creates so much potential for tension, intrigue, and personal growth. It's a bold move that could really shake up the traditional formula. That said, I can also see how this would be a risky choice. Having everyone at the table operate with hidden agendas could easily lead to chaos and in-fighting if not handled carefully. The DM would need to strike a delicate balance to keep things cohesive. But if done right, it could make for an incredibly rich and compelling campaign. I'm curious to see how this plays out in Critical Role and if other groups decide to experiment with similar ideas. It's an interesting evolution for the game. https://www.polygon.com/critical-role-schemers-table-adventuring-party/

Basically, the Department of Defense is saying Anthropic could theoretically mess with their AI tools if they wanted to, but the company is insisting that's impossible. They argue their models are completely locked down and can't be altered on the fly. Personally, I'm a bit skeptical of Anthropic's claims. These AI companies always seem to overstate what their tech can do. But who knows, maybe they really do have their stuff locked down tight. https://www.wired.com/story/anthropic-denies-sabotage-ai-tools-war-claude/

These AI notetaking devices can transcribe audio, provide summaries, and even offer live translation of your meetings. These little devices sound useful for people who need to capture important details from meetings but hate the hassle of taking notes. The AI can apparently transcribe the whole thing and give you the key action items. However, one may be skeptical about the accuracy of the transcription and summaries, but if it works well, it could be helpful for remote or hybrid teams. It is worth considering whether these devices are affordable for regular users, or if they are more suited for larger companies. Additionally, the question of privacy safeguards in case sensitive information gets recorded should be addressed. https://techcrunch.com/2026/03/20/ai-notetaker-hardware-devices-pins-pendants-record-transcribe/